93 related articles for article (PubMed ID: 21520097)
1. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Patel M; Hoffe S; Malafa M; Hodul P; Klapman J; Centeno B; Kim J; Helm J; Valone T; Springett G
J Surg Oncol; 2011 Aug; 104(2):155-61. PubMed ID: 21520097
[TBL] [Abstract][Full Text] [Related]
2. Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
Coveler AL; Pillarisetty VG; Koh WJ; Zhen DB; Park JO; King GG; Sham JG; Hannan LM; Mann GN; Baker KK; Redman MW; Swanson PE; Chiorean EG; Whiting SH
Pancreas; 2023 May; 52(5):e282-e287. PubMed ID: 37782886
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for borderline-resectable pancreatic cancer.
Okamura Y; Nishitai R; Sasaki N; Ito H; Sakamoto T; Itokawa Y; Kusumoto M; Nakai Y; Yamaoka T; Manaka D
Asia Pac J Clin Oncol; 2024 May; ():. PubMed ID: 38771310
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence.
O'Reilly D; Fou L; Hasler E; Hawkins J; O'Connell S; Pelone F; Callaway M; Campbell F; Capel M; Charnley R; Corrie P; Elliot D; Goodburn L; Jewell A; Joharchi S; McGeeney L; Mukherjee S; Oppong K; Whelan P; Primrose J; Neoptolemos J
Pancreatology; 2018 Dec; 18(8):962-970. PubMed ID: 30292643
[TBL] [Abstract][Full Text] [Related]
5. The Role of Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Cancer.
K GB; Koyyala VPB
Indian J Surg Oncol; 2024 May; 15(Suppl 2):315-321. PubMed ID: 38818012
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
[TBL] [Abstract][Full Text] [Related]
8. Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review.
Fiore M; Coppola A; Petrianni GM; Trecca P; D'Ercole G; Cimini P; Ippolito E; Caputo D; Beomonte Zobel B; Coppola R; Ramella S
J Gastrointest Oncol; 2023 Apr; 14(2):1114-1130. PubMed ID: 37201095
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
Katz MHG; Shi Q; Meyers J; Herman JM; Chuong M; Wolpin BM; Ahmad S; Marsh R; Schwartz L; Behr S; Frankel WL; Collisson E; Leenstra J; Williams TM; Vaccaro G; Venook A; Meyerhardt JA; O'Reilly EM
JAMA Oncol; 2022 Sep; 8(9):1263-1270. PubMed ID: 35834226
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
Wang C; Tan G; Zhang J; Fan B; Chen Y; Chen D; Yang L; Chen X; Duan Q; Maimaiti F; Du J; Lin Z; Gu J; Luo H
Front Oncol; 2022; 12():828223. PubMed ID: 35785193
[TBL] [Abstract][Full Text] [Related]
11. Vascular Resections in Association With Pancreatic Resections for Locally Advanced Pancreatic Cancer.
Bacalbasa N; Balescu I; Barbu I; Stiru O; Savu C; Pop L; Al Aloul A; Ursut B; Brasoveanu V; Petrea S
In Vivo; 2022; 36(2):1001-1006. PubMed ID: 35241562
[TBL] [Abstract][Full Text] [Related]
12. Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.
Blinn P; Shridhar R; Maramara T; Huston J; Meredith K
J Gastrointest Oncol; 2020 Oct; 11(5):1078-1089. PubMed ID: 33209499
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients.
Azab B; Macedo FI; Chang D; Ripat C; Franceschi D; Livingstone AS; Yakoub D
Clin Med Insights Oncol; 2020; 14():1179554920919402. PubMed ID: 32669884
[TBL] [Abstract][Full Text] [Related]
14. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
[TBL] [Abstract][Full Text] [Related]
15. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
Motoi F; Murakami Y; Okada KI; Matsumoto I; Uemura K; Satoi S; Sho M; Honda G; Fukumoto T; Yanagimoto H; Kinoshita S; Kurata M; Aoki S; Mizuma M; Yamaue H; Unno M;
World J Surg; 2019 Feb; 43(2):634-641. PubMed ID: 30298281
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.
Dhir M; Malhotra GK; Sohal DPS; Hein NA; Smith LM; O'Reilly EM; Bahary N; Are C
World J Surg Oncol; 2017 Oct; 15(1):183. PubMed ID: 29017581
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
Heinrich S; Lang H
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
Huang X; Knoble JL; Zeng M; Aguila FN; Patel T; Chambers LW; Hu H; Liu H
PLoS One; 2016; 11(12):e0166606. PubMed ID: 27935952
[TBL] [Abstract][Full Text] [Related]
20. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
